guardant


Also found in: Dictionary.
  • adj

Synonyms for guardant

looking forward

Related Words

References in periodicals archive ?
2, 2015 /PRNewswire/ -- Guardant Health, the leader in liquid biopsies, announced today that will accelerate the international commercialization of its industry-leading, non-invasive cancer sequencing diagnostic, Guardant360.
Companies described herein that specialize in ctDNA approaches to liquid biopsy include Agena Bioscience, Boreal Genomics, Chronix Biomedical, Genomic Health, Guardant Health, Inivata, Molecular MD, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, and Trovagene.
The increasing scientific and commercial adoption of Guardant360 has been unprecedented, and we attribute this to the unrivaled performance of our platform," said Helmy Eltoukhy, co-founder and CEO of Guardant Health.
20, 2015 /PRNewswire/ -- Guardant Health, the leader in liquid biopsies, announced the publication of two peer-reviewed studies demonstrating the superior performance of its non-invasive Guardant360 test over highly invasive tissue-based genomic testing.
In addition, Kalorama says that Biocept, Provista, Lifecode, Guardant Health, Biodesix, DiaCara, ACT Genomics are among the companies with 2015 financing announcements.
3, 2015 /PRNewswire/ -- Guardant Health, the leader in liquid biopsies, announced today that five abstracts highlighting the performance and clinical utility of Guardant360 on lung cancer patients have been accepted for oral and poster presentations at the International Association for the Study of Lung Cancer's 16th World Conference on Lung Cancer.
19, 2015 /PRNewswire/ -- Guardant Health and Flatiron Health today announced a strategic collaboration to build a proprietary, cloud-based information platform integrating liquid biopsy-based genomic testing with clinical treatment and outcomes data to support the accelerated development of targeted therapies for cancer.
June 24, 2015 /PRNewswire/ -- Guardant Health, the market leader in liquid biopsies, today announced that it has partnered with the National Cancer Institute (NCI)-funded SWOG on a study to use cell-free DNA testing to identify mechanisms of resistance and future treatment options in non-small cell lung cancer (NSCLC), one of the most pervasive forms of the disease.
May 27, 2015 /PRNewswire/ -- Guardant Health today announced that five abstracts submitted by the University of California, San Francisco; University of California, San Diego; and MD Anderson highlighting the performance and clinical utility of Guardant360 have been accepted for oral and poster presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29-June 2.
May 7, 2015 /PRNewswire/ -- Guardant Health, the leader in biopsy-free tumor genomic testing, today announced the hire of Mort Minaee as Vice President of Regulatory Affairs.
and PHILADELPHIA, April 21, 2015 /PRNewswire/ -- Guardant Health today announced new clinical utility data for its Guardant360 platform, which will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia.
and PHILADELPHIA, April 20, 2015 /PRNewswire/ -- Guardant Health, the leader in cell-free tumor DNA testing, is presenting data today on its findings from more than 2,000 clinical samples analyzed using Guardant360 at the 2015 American Association for Cancer Research (AACR) Annual Meeting.
April 8, 2015 /PRNewswire/ -- Guardant Health today announced that six abstracts submitted by leading cancer institutes highlighting the performance and clinical utility of Guardant360 have been accepted for presentation at the 2015 American Association for Cancer Research (AACR) Annual Meeting.
3, 2015 /PRNewswire/ -- Guardant Health today announced the completion of its Series C financing for approximately $50 million, bringing the Company's total funding to date to just under $100 million.
15, 2014 /PRNewswire/ -- Guardant Health, a healthcare company focused on the development and commercialization of oncology diagnostic products, today announced that it has received accreditation by the College of American Pathologists (CAP) based on results of a recent on-site laboratory inspection.